In vitro synergy of ticarcillin/clavulanate in combination with aztreonam and ceftolozane/tazobactam against SPM-1-producing Pseudomonas aeruginosa strains.
Diagn Microbiol Infect Dis
; 100(2): 115343, 2021 Jun.
Article
in En
| MEDLINE
| ID: mdl-33652305
Minimal inhibitory concentrations (MICs) of ticarcillin/clavulanic acid (TLc), ceftolozane/tazobactam (C/T), and aztreonam (AT) were determined for 6 SPM-1-producing Pseudomonas aeruginosa (PSA) using Etest® strips and the synergistic effect of such antimicrobials against was evaluated by gradient diffusion strip crossing (GDSC) test. The fraction inhibitory concentration indexes (FICI) were calculated and showed a synergistic (nâ¯=â¯3) and additive (nâ¯=â¯2) effects of TLcâ¯+â¯AT against SPM-1 producers, while TLcâ¯+â¯C/T combination caused no effect. Average MIC reduction of TLc and AT by GDSC was 3-fold and 2-fold dilutions, respectively. Thus, TLcâ¯+â¯AT might be a candidate as a combination therapy to treat SPM-1-producing PSA infections.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pseudomonas aeruginosa
/
Beta-Lactamases
/
Anti-Bacterial Agents
Language:
En
Journal:
Diagn Microbiol Infect Dis
Year:
2021
Document type:
Article
Affiliation country:
Brazil
Country of publication:
United States